Benzinga | May 25, 2021 08:55AM EDT

B. Riley Securities Downgrades Intercept Pharmaceuticals to Neutral

B. Riley Securities analyst Mayank Mamtani downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Buy to Neutral.